|drug3709||blood tests Wiki||1.00|
|drug501||Breath Biopsy Analysis Wiki||1.00|
|drug2115||Nasopharyngeal swabs Wiki||0.71|
|D001172||Arthritis, Rheumatoid NIH||0.30|
There is one clinical trial.
The purpose of this study is to assess whether immunosuppressive therapies used by patients with chronic inflammatory rheumatic diseases have an impact on the viral load and the humoral and cellular responses during viral infection with SarSCoV2, compared to members of their family cluster infected with the same viral strain.
Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNAMeasure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs Time: up to Day 30
Description: Nasopharyngeal swabs : Detection of SarS-Cov-2 RNAMeasure: Detection of SarS-Cov-2 RNA in feces and nasopharyngeal swabs Time: between Day 30 and Day 90
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports